Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term pediatric atogepant extension study in migraine
NL-OMON60902Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of atogepant in migraine, sponsored by AbbVie Inc. Primary endpoints: Safety and tolerability of atogepant, Adverse event monitoring and 7 more. Started Feb 2024; status: recruiting.
02
Drugs
atogepant
03
Conditions
migraine
Beyond the preview
Go deeper on NL-OMON60902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60902.